Abstract
Two hundred and seventeen patients with advanced gastric cancer were classified according to the resectability of the tumour into two groups: I, resectable (non-radical surgery), 99 patients, and II, non-resectable carcinoma, 118 patients. Within each group patients were randomly assigned to receive 5-fluorouracil (5-FU) + BCG, 5-FU, or no further treatment (surgery only). BCG was given by scarification. A 2-year follow-up is reported. The group of patients with resectable tumours and receiving chemoimmunotherapy had a statistically significant prolongation of survival compared with the 5-FU and surgery only groups. No differences in survival were observed between these treatment modalities in patients with non-resectable tumour. These observations indicate that chemoimmunotherapy may be of benefit for a selected group of patients with gastric cancer.
Keywords: Carcinoma, Gastric Cancer, Cancer Research, Group Patient, Treatment Modality
References
- 1.Ambus U, Falk RE, Landi S, Bugala R, Langer B. Randomized trials of chemoimmunotherapy for resectable and non-resectable gastrointestinal cancer. Dev Biol Stand. 1978;38:541. [PubMed] [Google Scholar]
- 2.Bitran JD, Desser RK, Kozloff MF, Billings AA, Shapiro CM. Treatment of metastatic pancreatic and gastric adenocarcinomas with 5-fluorouracil, adriamycin and mitomycin C (FAM) Cancer Treat Rep. 1979;63:2049. [PubMed] [Google Scholar]
- 3.Burdette WJ, Gehan EA. Planing and analysis of clinical studies. Springfield: Thomas; 1970. p. 72. [Google Scholar]
- 4.Colton T. Statistics in medicine. Boston: Little Brown; 1974. p. 244. [Google Scholar]
- 5.Clarysse A, Kenis Y, Mathé G. Cancer chemotherapy. Berlin Heidelberg New York: Springer; 1976. p. 424. [Google Scholar]
- 6.Edynak EM, Oishi N, Gordon BL, Deich A. Immunotherapy of carcinoma of the stomach: a status report. Hawaii Med J. 1977;36:71. [PubMed] [Google Scholar]
- 7.Ishikawa Y, Fukushima M, Machida S, Kakuta H, Nishikawa T, Fukuda S. Specific cancer immunotherapy adjunctive to surgery for advanced gastric cancer: a report of six long-term survivors. Gastroenterology. 1978;13:54. doi: 10.1007/BF02774155. [DOI] [PubMed] [Google Scholar]
- 8.Mathé G. Systemic active immunotherapy is shifting from middle ages to renaissance period. I. The multiplication of randomized trials showing significant effect of active immunotherapy on residual minimal disease. Cancer Immunol Immunother. 1978;5:149. [Google Scholar]
- 9.Mathé G, Amiel JL, Schwarzenburg L, Schneider M, Caltan A, Schlumberger JR, Hayat M, de Vassal F. Active immunotherapy for acute lymphoblastic leukemia. Lancet. 1969;I:697. doi: 10.1016/s0140-6736(69)92648-8. [DOI] [PubMed] [Google Scholar]
- 10.Mavligit CM, Gutterman JU, Bergess MA, Speer JF, Reed RC, Martin RC, McBride CM, Copeland EM, Gehan EA, Hersh EM. Immunotherapy. Its possible application in the management of large-bowel cancer. Am J Dig Dis. 1974;19:1047. doi: 10.1007/BF01255789. [DOI] [PubMed] [Google Scholar]
- 11.McDonald JS, Wolley PV, Smythe T, Vendo W, Hoth D, Schein PS. 5-Fluorouracil, adriamycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer. 1979;44:42. doi: 10.1002/1097-0142(197907)44:1<42::aid-cncr2820440108>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
- 12.Moertel CG, Engstrom P, Lavin PT, Gelber RD, Carbone PP. Chemotherapy of gastric and pancreatic carcinoma. Surgery. 1979;85:509. [PubMed] [Google Scholar]
- 13.Morton DL, Goodnight JE., Jr Clinical trials of immunotherapy. Present status. Cancer. 1978;42:2224. doi: 10.1002/1097-0142(197811)42:5<2224::aid-cncr2820420521>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
- 14.Schein PS (1980) Chemotherapy of gastric cancer. International Congress on Diagnosis and Treatment of Upper Gastro-intestinal Tumours, Mainz, 9–11 Sept. 1980. Preprint of selected papers, p 65
- 15.Schwarzenberg L, Simmler MC, Pico JL. Human toxicology of BCG applied in cancer immunotherapy. Cancer Immunol Immunother. 1976;1:69. [Google Scholar]
- 16.Torisu M, Miyahara T, Yamamoto T, Harda M, Fujiwara H, Kitamura Y, Jimi M, Oshato K, Tanaka J, Fukawa M. Fundamental and practical aspects of BCG immunotherapy in patients with late stage of gastric cancer. Gann Monogr Cancer Res. 1978;21:173. [Google Scholar]
- 17.Yamamura Y, Sakatani M, Ogura T, Azuma I. Adjuvant immunotherapy of lung cancer with BCG cell wall skeleton (BCG-CWS) Cancer. 1979;43:1314. doi: 10.1002/1097-0142(197904)43:4<1314::aid-cncr2820430420>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]